Analysis of SARS-CoV-2 infection in human lung organoids
- Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
- Total publications:0 publications
Grant number: 01KI2058
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$423,607.04Funder
Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)Principal Investigator
Prof. Stephanie PfänderResearch Location
GermanyLead Research Institution
Ruhr Universität BochumResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Disease pathogenesis
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Abstract: "Organoids are three dimensional tissues derived from stem cells. The usage of human induced pluripotent stem cells (iPSC) enables the differentiation into organoids with human tissue-like features. iPSC can also be used to differentiate human lung organoids (HLO). The organization of HLOs is similar to the native lung, e.g. these organoids contain upper airway-like epithelium with basal cells, immature ciliated cells, smooth muscle, myofibroblasts as well as alveolar-like cell types. Thus, HLOs offer an excellent model to study human lung diseases like COVID-19. Moreover, the iPS derived organoids overcome several of the limitations of currently used biopsy lung derived models (availability of alveolar epithelial type II cells (AT2), inter biopsy variance).Within this proposal we aim to elaborate basics for the establishment of a high-throughput approach (differentiate HLOs with low variance). HLOs will be characterized using cryo-sectioning and immunofluorescence analysis upon SARS-CoV-2 infection. We aim to study viral replication kinetics and host responses. We recently contributed to the establishment of the first reverse genetics system for SARS-CoV-2 offering the flexibility of using reporter viruses for a screening approach. Finally, we will test our system upon treatment with established antiviral compounds and aim to set up screening approaches to test antiviral compound libraries. Our approach offers a state-of-the-art model to study SARS-CoV-2 derived pathology and paves the way for the identification of effective antiviral drugs at high throughput level."; Research Type: discovery; Study population: not applicable